Hua Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hua Hao has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Fen Xu
Department of General Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China
8 shared publicationsJian Zheng
Department of Pathology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China
8 shared publicationsLiping Yan
Department of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, China
5 shared publicationsBing Zhou
Department of Pathology, Second Affiliated Hospital of Jiujiang University, Jiujiang, China
4 shared publicationsLan Lin
Department of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, China
4 shared publicationsQingyu Wang
Department of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, PR China
4 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 2003726
Fibroblast mechanopharmacology: mechanical regulation of fibroblast states and therapeutic response
Fibroblasts integrate mechanical and biochemical signals to maintain tissue integrity, yet sustained mechanical remodeling drives pathological phenotypes and modifies therapeutic responses. Matrix stiffness, collagen structure, tissue loading and fluid forces activate coordinated mechanosensory systems that regulate cytoskeletal, transcriptional, nuclear and metabolic programs. These pathways control overlapping repair, inflammatory, contractile and senescent fibroblast states, whose persistence and reversibility depend on tissue context and mechanical history. This review introduces fibroblast mechanopharmacology as a framework connecting the mechanical microenvironment, fibroblast plasticity and drug responses in fibrosis, cancer, cardiovascular remodeling and chronic inflammation. We discuss how fibroblast–matrix feedback affects drug delivery, signaling reliance, stable cellular functions and immune infiltration, shaping treatment efficacy independently of target expression. Such mechanisms support combined strategies including matrix normalization, mechanotransduction blockade, antifibrotic therapy, cell-state reprogramming and stromal–immune co-targeting. We also address how mechanically tuned cultures and human tissue models separate poor drug exposure from changed cellular sensitivity, and distinguish blocking fibroblast activation from reversing established dysfunction. Combining mechanical readouts, fibroblast-state profiling and functional drug testing can tailor interventions to disease-driving mechanical conditions and cellular dependencies. This perspective advances therapies designed around mechanical context and state reversibility without disrupting normal tissue repair.
- 12 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 2003726
Open AccessFibroblast mechanopharmacology: mechanical regulation of fibroblast states and therapeutic response
Fibroblasts integrate mechanical and biochemical signals to maintain tissue integrity, yet sustained mechanical remodeling drives pathological phenotypes and modifies therapeutic responses. Matrix stiffness, collagen structure, tissue loading and fluid forces activate coordinated mechanosensory systems that regulate cytoskeletal, transcriptional, nuclear and metabolic programs. These pathways control overlapping repair, inflammatory, contractile and senescent fibroblast states, whose persistence and reversibility depend on tissue context and mechanical history. This review introduces fibroblast mechanopharmacology as a framework connecting the mechanical microenvironment, fibroblast plasticity and drug responses in fibrosis, cancer, cardiovascular remodeling and chronic inflammation. We discuss how fibroblast–matrix feedback affects drug delivery, signaling reliance, stable cellular functions and immune infiltration, shaping treatment efficacy independently of target expression. Such mechanisms support combined strategies including matrix normalization, mechanotransduction blockade, antifibrotic therapy, cell-state reprogramming and stromal–immune co-targeting. We also address how mechanically tuned cultures and human tissue models separate poor drug exposure from changed cellular sensitivity, and distinguish blocking fibroblast activation from reversing established dysfunction. Combining mechanical readouts, fibroblast-state profiling and functional drug testing can tailor interventions to disease-driving mechanical conditions and cellular dependencies. This perspective advances therapies designed around mechanical context and state reversibility without disrupting normal tissue repair.
- Open Access
- 4 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2540
Natural Products Targeting Regulated Cell Death in Bladder Cancer: Pathway Mechanisms, Crosstalk and Intravesical Translation
The frequent recurrence and treatment resistance of bladder cancer have prompted interest in natural products that modulate regulated cell death (RCD). Although several compounds have shown activity in experimental models, their mechanisms of action and relevance to intravesical treatment remain unclear. This narrative review examines chemically defined natural compounds, metabolites, semisynthetic derivatives, and compositionally characterized extracts or preparations, and relates their effects on RCD to pathway crosstalk and intravesical delivery. We distinguish functional evidence of death pathway dependence from changes in associated markers and consider how resistance, treatment conditions, and cell type influence the response. Apoptosis is the most extensively studied pathway, involving mitochondrial priming, death receptor signaling, and suppression of survival networks. Ferroptosis has the strongest mechanistic support among non-apoptotic pathways, as evidenced by iron chelation, inhibition of lipid peroxidation, glutathione peroxidase 4 engagement, and perturbation of antioxidant defenses. Evidence for necroptosis, pyroptosis, and cuproptosis is limited; no direct evidence for disulfidptosis induced by a natural small molecule acting alone was identified in the reviewed bladder cancer literature. Emerging studies also report disulfidptosis-associated effects of selected formulations and anoikis-related responses, although these findings remain specific to the interventions studied. Autophagy can protect cells or contribute to cell death; however, impaired degradation can complicate the interpretation of autophagy markers. The balance between death pathways can shift with exposure and resistance states. Cell type also matters: inducing ferroptosis in tumor cells may support tumor control, whereas suppressing ferroptotic dysfunction in macrophages can preserve antitumor immunity. Translation remains limited by the separation between mechanism-focused studies and human intravesical trials, which have largely examined different agents. The former seldom assess tissue exposure or repeated-dose urothelial safety, whereas the latter report clinical activity and short-term tolerability without establishing dependence on a specific RCD pathway. Further development requires studies that link intravesical retention and tissue exposure to target engagement, and functionally test RCD while assessing antitumor efficacy and normal urothelial safety under repeated dosing.
- 4 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2540
Open AccessNatural Products Targeting Regulated Cell Death in Bladder Cancer: Pathway Mechanisms, Crosstalk and Intravesical Translation
The frequent recurrence and treatment resistance of bladder cancer have prompted interest in natural products that modulate regulated cell death (RCD). Although several compounds have shown activity in experimental models, their mechanisms of action and relevance to intravesical treatment remain unclear. This narrative review examines chemically defined natural compounds, metabolites, semisynthetic derivatives, and compositionally characterized extracts or preparations, and relates their effects on RCD to pathway crosstalk and intravesical delivery. We distinguish functional evidence of death pathway dependence from changes in associated markers and consider how resistance, treatment conditions, and cell type influence the response. Apoptosis is the most extensively studied pathway, involving mitochondrial priming, death receptor signaling, and suppression of survival networks. Ferroptosis has the strongest mechanistic support among non-apoptotic pathways, as evidenced by iron chelation, inhibition of lipid peroxidation, glutathione peroxidase 4 engagement, and perturbation of antioxidant defenses. Evidence for necroptosis, pyroptosis, and cuproptosis is limited; no direct evidence for disulfidptosis induced by a natural small molecule acting alone was identified in the reviewed bladder cancer literature. Emerging studies also report disulfidptosis-associated effects of selected formulations and anoikis-related responses, although these findings remain specific to the interventions studied. Autophagy can protect cells or contribute to cell death; however, impaired degradation can complicate the interpretation of autophagy markers. The balance between death pathways can shift with exposure and resistance states. Cell type also matters: inducing ferroptosis in tumor cells may support tumor control, whereas suppressing ferroptotic dysfunction in macrophages can preserve antitumor immunity. Translation remains limited by the separation between mechanism-focused studies and human intravesical trials, which have largely examined different agents. The former seldom assess tissue exposure or repeated-dose urothelial safety, whereas the latter report clinical activity and short-term tolerability without establishing dependence on a specific RCD pathway. Further development requires studies that link intravesical retention and tissue exposure to target engagement, and functionally test RCD while assessing antitumor efficacy and normal urothelial safety under repeated dosing.
- Open Access
- 12 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8144
LIMCH1 in Cancer: A Context-Dependent Modulator Beyond the Tumor Suppressor–Oncogene Dichotomy
LIM and calponin homology domain-containing protein 1 (LIMCH1) has recently gained attention as a functionally perplexing factor in human cancers, with studies attributing both tumor-suppressive and tumor-promoting properties that defy simple categorization. Originally described as an actin-associated cytoskeletal protein that promotes non-muscle myosin-IIA (NM-IIA) activity and thereby curtails cell migration, LIMCH1 has more recently been linked to diverse oncogenic pathways across a range of tumor types. In lung adenocarcinoma and clear-cell renal cell carcinoma, diminished LIMCH1 expression is associated with more aggressive clinical behavior and reduced overall survival, aligning with a tumor-suppressive role. By comparison, in triple-negative and invasive breast cancers and in cervical squamous cell carcinoma, increased LIMCH1 expression correlates with enhanced metastatic spread, immune escape, and unfavorable outcomes, suggesting a pro-oncogenic function. In this review, findings from over 30 published studies are integrated with an original TCGA pan-cancer expression and survival analysis to propose that LIMCH1 is best understood as a context-dependent conditional regulator rather than as a classical tumor suppressor or oncogene. Based on the available evidence, we propose a hypothesis-generating conceptual framework in which its ultimate phenotypic effect is shaped by three interacting contextual determinants: (i) TP53 mutation status (determining whether the HUWE1-p53 axis is intact); (ii) tumor matrix stiffness (modulating actomyosin contractility and migration mode); and (iii) upstream signaling cues (e.g., MAPK/ERK, TGFβ). Of note, other tumor-lineage and microenvironmental factors may also contribute and warrant further investigation. This framework resolves the apparent functional duality of LIMCH1 in a cancer type-specific manner and provides critical guidance for future mechanistic research, standardized detection workflows, and the clinical translation of LIMCH1-based biomarkers.
- 12 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8144
Open AccessLIMCH1 in Cancer: A Context-Dependent Modulator Beyond the Tumor Suppressor–Oncogene Dichotomy
LIM and calponin homology domain-containing protein 1 (LIMCH1) has recently gained attention as a functionally perplexing factor in human cancers, with studies attributing both tumor-suppressive and tumor-promoting properties that defy simple categorization. Originally described as an actin-associated cytoskeletal protein that promotes non-muscle myosin-IIA (NM-IIA) activity and thereby curtails cell migration, LIMCH1 has more recently been linked to diverse oncogenic pathways across a range of tumor types. In lung adenocarcinoma and clear-cell renal cell carcinoma, diminished LIMCH1 expression is associated with more aggressive clinical behavior and reduced overall survival, aligning with a tumor-suppressive role. By comparison, in triple-negative and invasive breast cancers and in cervical squamous cell carcinoma, increased LIMCH1 expression correlates with enhanced metastatic spread, immune escape, and unfavorable outcomes, suggesting a pro-oncogenic function. In this review, findings from over 30 published studies are integrated with an original TCGA pan-cancer expression and survival analysis to propose that LIMCH1 is best understood as a context-dependent conditional regulator rather than as a classical tumor suppressor or oncogene. Based on the available evidence, we propose a hypothesis-generating conceptual framework in which its ultimate phenotypic effect is shaped by three interacting contextual determinants: (i) TP53 mutation status (determining whether the HUWE1-p53 axis is intact); (ii) tumor matrix stiffness (modulating actomyosin contractility and migration mode); and (iii) upstream signaling cues (e.g., MAPK/ERK, TGFβ). Of note, other tumor-lineage and microenvironmental factors may also contribute and warrant further investigation. This framework resolves the apparent functional duality of LIMCH1 in a cancer type-specific manner and provides critical guidance for future mechanistic research, standardized detection workflows, and the clinical translation of LIMCH1-based biomarkers.
- Open Access
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1887125
UNC93B1 drives IL-6/STAT3-dependent tumor–macrophage crosstalk and epithelial–mesenchymal transition in breast cancer
Background: Lipid metabolic reprogramming is increasingly recognized as a driver of breast cancer progression; however, how lipid metabolism-associated risk states are translated into immune remodeling and epithelial–mesenchymal transition (EMT) remains unclear. This study aimed to identify a lipid metabolism-related regulator that mediates tumor–macrophage crosstalk and to experimentally define its role in breast cancer progression. Methods: Lipid metabolism-related immune regulatory candidates were identified through integrated bulk transcriptomic, machine-learning, single-cell, and spatial transcriptomic analyses. UNC93B1 was prioritized for experimental validation using immunohistochemistry, gain- and loss-of-function assays, tumor cell–macrophage co-culture, ELISA, IL-6 neutralization, and STAT3 inhibition/rescue experiments. Results: Integrated multi-omics analysis prioritized UNC93B1 as a lipid metabolism-associated immune regulatory hub in breast cancer. UNC93B1 was associated with high lipid metabolism risk status, invasive tumor phenotypes, and stronger expression in aggressive molecular contexts, particularly HER2-enriched and triple-negative breast cancer samples. Single-cell and spatial transcriptomic analyses further linked UNC93B1 to myeloid/macrophage-enriched states, M2-like macrophage polarization, and Toll-like receptor-related immune niches. Experimentally, UNC93B1 knockdown suppressed breast cancer cell proliferation, migration, invasion, STAT3 activation, and EMT, whereas UNC93B1 overexpression produced the opposite effects. In tumor cell–macrophage co-culture systems, tumor cell-derived UNC93B1 enhanced IL-6 secretion, activated STAT3 signaling in macrophages, and promoted M2-like polarization. Reciprocally, macrophage-associated IL-6/STAT3 signaling reinforced EMT and invasive behavior in breast cancer cells. IL-6 neutralization and STAT3 inhibition markedly disrupted this paracrine feedback loop, confirming that UNC93B1 promotes breast cancer progression through an IL-6/STAT3-dependent tumor–macrophage crosstalk axis. Conclusion: This study identifies UNC93B1 as a macrophage-associated immune regulatory factor linked to lipid metabolism-related risk in breast cancer. Integrated multi-omics analyses and functional experiments demonstrate that UNC93B1 promotes IL-6/STAT3-dependent tumor–macrophage communication, thereby enhancing M2-like macrophage polarization, EMT activation, and invasive tumor behavior. These findings support UNC93B1 as a potential biomarker and intervention target in immunologically aggressive breast cancer. However, the direct role of UNC93B1 in lipid metabolic remodeling remains to be validated through lipidomic and metabolic flux analyses, and its tumor- and microenvironment-dependent effects require further confirmation in orthotopic or immune-competent in vivo breast cancer models.
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1887125
Open AccessUNC93B1 drives IL-6/STAT3-dependent tumor–macrophage crosstalk and epithelial–mesenchymal transition in breast cancer
Background: Lipid metabolic reprogramming is increasingly recognized as a driver of breast cancer progression; however, how lipid metabolism-associated risk states are translated into immune remodeling and epithelial–mesenchymal transition (EMT) remains unclear. This study aimed to identify a lipid metabolism-related regulator that mediates tumor–macrophage crosstalk and to experimentally define its role in breast cancer progression. Methods: Lipid metabolism-related immune regulatory candidates were identified through integrated bulk transcriptomic, machine-learning, single-cell, and spatial transcriptomic analyses. UNC93B1 was prioritized for experimental validation using immunohistochemistry, gain- and loss-of-function assays, tumor cell–macrophage co-culture, ELISA, IL-6 neutralization, and STAT3 inhibition/rescue experiments. Results: Integrated multi-omics analysis prioritized UNC93B1 as a lipid metabolism-associated immune regulatory hub in breast cancer. UNC93B1 was associated with high lipid metabolism risk status, invasive tumor phenotypes, and stronger expression in aggressive molecular contexts, particularly HER2-enriched and triple-negative breast cancer samples. Single-cell and spatial transcriptomic analyses further linked UNC93B1 to myeloid/macrophage-enriched states, M2-like macrophage polarization, and Toll-like receptor-related immune niches. Experimentally, UNC93B1 knockdown suppressed breast cancer cell proliferation, migration, invasion, STAT3 activation, and EMT, whereas UNC93B1 overexpression produced the opposite effects. In tumor cell–macrophage co-culture systems, tumor cell-derived UNC93B1 enhanced IL-6 secretion, activated STAT3 signaling in macrophages, and promoted M2-like polarization. Reciprocally, macrophage-associated IL-6/STAT3 signaling reinforced EMT and invasive behavior in breast cancer cells. IL-6 neutralization and STAT3 inhibition markedly disrupted this paracrine feedback loop, confirming that UNC93B1 promotes breast cancer progression through an IL-6/STAT3-dependent tumor–macrophage crosstalk axis. Conclusion: This study identifies UNC93B1 as a macrophage-associated immune regulatory factor linked to lipid metabolism-related risk in breast cancer. Integrated multi-omics analyses and functional experiments demonstrate that UNC93B1 promotes IL-6/STAT3-dependent tumor–macrophage communication, thereby enhancing M2-like macrophage polarization, EMT activation, and invasive tumor behavior. These findings support UNC93B1 as a potential biomarker and intervention target in immunologically aggressive breast cancer. However, the direct role of UNC93B1 in lipid metabolic remodeling remains to be validated through lipidomic and metabolic flux analyses, and its tumor- and microenvironment-dependent effects require further confirmation in orthotopic or immune-competent in vivo breast cancer models.
- Open Access
CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions
Cyclin-dependent kinase 4/6 inhibitors have fundamentally changed the management of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. However, these drugs are not interchangeable and the field is moving away from the notion of a uniform “class effect.” In early breast cancer, adjuvant abemaciclib and ribociclib improve invasive disease-free survival in patients at a high risk of recurrence, whereas palbociclib does not. This difference likely stems from agent-specific pharmacological profiles, differences in trial design, and patient selection, rather than simply dosing nuances. In metastatic breast cancer, all three agents prolong progression-free survival when combined with endocrine therapy, but only ribociclib and potentially abemaciclib have shown an overall survival advantage. In addition, resistance remains a major obstacle in clinical practice. We propose that resistance mechanisms can be meaningfully grouped into two categories: target-driven (e.g., RB1 loss, CDK6 amplification) and bypass-driven (e.g., ESR1 mutations, PI3K/AKT pathway activation, APOBEC3-mediated mutagenesis). Distinguishing between these classes helps in the design of rational sequencing algorithms and combinatorial regimens. Emerging strategies, such as next-generation protein degraders, oral selective estrogen receptor degraders, antibody–drug conjugates, and inhibition of autophagy, are promising methods for overcoming resistance. Moving forward, the greatest need in breast cancer treatment will be not simply developing additional agents but using current therapies more intelligently by refining biomarker-guided patient selection, tailoring treatment duration, and ensuring broad global access.
Open AccessCDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions
Cyclin-dependent kinase 4/6 inhibitors have fundamentally changed the management of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. However, these drugs are not interchangeable and the field is moving away from the notion of a uniform “class effect.” In early breast cancer, adjuvant abemaciclib and ribociclib improve invasive disease-free survival in patients at a high risk of recurrence, whereas palbociclib does not. This difference likely stems from agent-specific pharmacological profiles, differences in trial design, and patient selection, rather than simply dosing nuances. In metastatic breast cancer, all three agents prolong progression-free survival when combined with endocrine therapy, but only ribociclib and potentially abemaciclib have shown an overall survival advantage. In addition, resistance remains a major obstacle in clinical practice. We propose that resistance mechanisms can be meaningfully grouped into two categories: target-driven (e.g., RB1 loss, CDK6 amplification) and bypass-driven (e.g., ESR1 mutations, PI3K/AKT pathway activation, APOBEC3-mediated mutagenesis). Distinguishing between these classes helps in the design of rational sequencing algorithms and combinatorial regimens. Emerging strategies, such as next-generation protein degraders, oral selective estrogen receptor degraders, antibody–drug conjugates, and inhibition of autophagy, are promising methods for overcoming resistance. Moving forward, the greatest need in breast cancer treatment will be not simply developing additional agents but using current therapies more intelligently by refining biomarker-guided patient selection, tailoring treatment duration, and ensuring broad global access.
- Open Access
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1859041
S100A8/A9 as a key player in colorectal cancer: from diagnosis to therapeutic targeting
S100A8/A9, a key member of the calcium-binding protein family, exerts multiple biological effects through its aberrant expression, and serves as an important regulatory factor in the development and progression of colorectal cancer (CRC). Its activity remodels the tumor microenvironment (TME) by amplifying inflammatory responses, establishing immunotolerant conditions, promoting metastatic tumor phenotypes, and forming pre-metastatic and angiogenic niches. These processes suppress anti-tumor immunity, enhance tumor invasion and metastasis, and are associated with poorer prognosis, particularly in advanced-stage CRC. Despite the complexity of its regulatory network, S100A8/A9 represents a valuable potential therapeutic target. This review systematically summarizes the biological properties, clinical significance, and tumor microenvironment-related mechanisms of S100A8/A9 in CRC, with emphasis on inflammation, immune regulation, invasion, metastasis, biomarker potential, and therapeutic targeting. We further discuss emerging S100A8/A9-based intervention strategies, including direct molecular targeting, receptor-pathway blockade, natural-product modulation, combination therapy, and precision-delivery approaches, aiming to clarify both the translational opportunities and limitations of S100A8/A9-directed precision management in CRC.
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1859041
Open AccessS100A8/A9 as a key player in colorectal cancer: from diagnosis to therapeutic targeting
S100A8/A9, a key member of the calcium-binding protein family, exerts multiple biological effects through its aberrant expression, and serves as an important regulatory factor in the development and progression of colorectal cancer (CRC). Its activity remodels the tumor microenvironment (TME) by amplifying inflammatory responses, establishing immunotolerant conditions, promoting metastatic tumor phenotypes, and forming pre-metastatic and angiogenic niches. These processes suppress anti-tumor immunity, enhance tumor invasion and metastasis, and are associated with poorer prognosis, particularly in advanced-stage CRC. Despite the complexity of its regulatory network, S100A8/A9 represents a valuable potential therapeutic target. This review systematically summarizes the biological properties, clinical significance, and tumor microenvironment-related mechanisms of S100A8/A9 in CRC, with emphasis on inflammation, immune regulation, invasion, metastasis, biomarker potential, and therapeutic targeting. We further discuss emerging S100A8/A9-based intervention strategies, including direct molecular targeting, receptor-pathway blockade, natural-product modulation, combination therapy, and precision-delivery approaches, aiming to clarify both the translational opportunities and limitations of S100A8/A9-directed precision management in CRC.
- 9 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1030, 179131
Targeting Lipid Metabolism Enzymes in Breast Cancer: Mechanistic Basis and Therapeutic Vulnerabilities
- 9 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1030, 179131
Targeting Lipid Metabolism Enzymes in Breast Cancer: Mechanistic Basis and Therapeutic Vulnerabilities
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1696219
Case Report: A case of cervical burkitt lymphoma and literature review
Primary cervical Burkitt’s lymphoma (BL) is an extremely rare malignancy. This report describes the case of a 55-year-old woman admitted to the hospital with irregular vaginal bleeding. Histologically, the tumor cells demonstrated infiltrative growth, relatively uniform basophilic cytoplasm. Immunohistochemical analysis revealed positivity for B-cell markers (CD20, CD79α, etc.), with MYC expression in approximately 80% of cells, fluorescence in situ hybridization staining showed positivity for MYC translocation and molecular testing confirmed IG rearrangement. The diagnosis of Burkitt’s lymphoma is based on its distinctive histological morphology in combination with immunohistochemistry and molecular testing.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1696219
Open AccessCase Report: A case of cervical burkitt lymphoma and literature review
Primary cervical Burkitt’s lymphoma (BL) is an extremely rare malignancy. This report describes the case of a 55-year-old woman admitted to the hospital with irregular vaginal bleeding. Histologically, the tumor cells demonstrated infiltrative growth, relatively uniform basophilic cytoplasm. Immunohistochemical analysis revealed positivity for B-cell markers (CD20, CD79α, etc.), with MYC expression in approximately 80% of cells, fluorescence in situ hybridization staining showed positivity for MYC translocation and molecular testing confirmed IG rearrangement. The diagnosis of Burkitt’s lymphoma is based on its distinctive histological morphology in combination with immunohistochemistry and molecular testing.
- Open Access
- 22 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1610820
Small intestinal NK/T-cell lymphoma with malignant peritoneal effusion as the first symptom: a case report and literature review
Introduction: Small intestinal NK/T-cell lymphoma (NK/T-L) is a rare condition, and cases presenting with malignant peritoneal effusion as the initial symptoms are not well-documented. We report a unique case that contributes to the understanding of this rare disease.Case report: A 47-year-old man was admitted to the hospital with a chief complaint of abdominal distension and weight loss persisting for over 2 months. Imaging studies revealed ascites and localized thickening of the small intestine. Paracentesis cytology revealed a significant presence of small-to-medium-sized lymphoid cells. Immunohistochemistry confirmed a diagnosis of T-cell lymphoma. Histological examination confirmed primary NK/T-L of the small intestine after PET-CT excluded metastases from other sites. Despite aggressive chemotherapy, the patient’s condition deteriorated, resulting in his death 4 months later.Discussion: This case highlights the importance of considering small intestinal NK/T-L in patients with abdominal symptoms and malignant peritoneal effusion. The aggressive nature and poor prognosis of this disease pose challenges in diagnosis and treatment. Increased awareness among clinicians and pathologists is crucial for early detection and improved patient outcomes.
- 22 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1610820
Open AccessSmall intestinal NK/T-cell lymphoma with malignant peritoneal effusion as the first symptom: a case report and literature review
Introduction: Small intestinal NK/T-cell lymphoma (NK/T-L) is a rare condition, and cases presenting with malignant peritoneal effusion as the initial symptoms are not well-documented. We report a unique case that contributes to the understanding of this rare disease.Case report: A 47-year-old man was admitted to the hospital with a chief complaint of abdominal distension and weight loss persisting for over 2 months. Imaging studies revealed ascites and localized thickening of the small intestine. Paracentesis cytology revealed a significant presence of small-to-medium-sized lymphoid cells. Immunohistochemistry confirmed a diagnosis of T-cell lymphoma. Histological examination confirmed primary NK/T-L of the small intestine after PET-CT excluded metastases from other sites. Despite aggressive chemotherapy, the patient’s condition deteriorated, resulting in his death 4 months later.Discussion: This case highlights the importance of considering small intestinal NK/T-L in patients with abdominal symptoms and malignant peritoneal effusion. The aggressive nature and poor prognosis of this disease pose challenges in diagnosis and treatment. Increased awareness among clinicians and pathologists is crucial for early detection and improved patient outcomes.
- Open Access
- 18 July 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1636992
Biomarkers in spinal muscular atrophy
Spinal muscular atrophy is a hereditary disorder leading to severe neuromuscular impairment. With the introduction of disease-modifying therapies in recent years, the role of biomarkers has expanded from aiding diagnosis to monitoring treatment responses, prognostic assessment, and the development of individualized treatment strategies. This review systematically summarizes biomarkers in the field of spinal muscular atrophy, including physiological indicators, functional assessments, imaging features, and molecular markers, which are derived from the analysis of different tissues from human patients and animal models. This article provides a concise summary of the classic biomarkers widely used in current clinical practice and introduces the potential new biomarkers revealed by the latest research. It focuses on discussing the expression patterns, clinical correlations, and applicable conditions of various types of biomarkers, with the aim of providing more accurate basis for disease stratification, efficacy prediction, and treatment decision-making.
- 18 July 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1636992
Open AccessBiomarkers in spinal muscular atrophy
Spinal muscular atrophy is a hereditary disorder leading to severe neuromuscular impairment. With the introduction of disease-modifying therapies in recent years, the role of biomarkers has expanded from aiding diagnosis to monitoring treatment responses, prognostic assessment, and the development of individualized treatment strategies. This review systematically summarizes biomarkers in the field of spinal muscular atrophy, including physiological indicators, functional assessments, imaging features, and molecular markers, which are derived from the analysis of different tissues from human patients and animal models. This article provides a concise summary of the classic biomarkers widely used in current clinical practice and introduces the potential new biomarkers revealed by the latest research. It focuses on discussing the expression patterns, clinical correlations, and applicable conditions of various types of biomarkers, with the aim of providing more accurate basis for disease stratification, efficacy prediction, and treatment decision-making.